Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
2.150
-0.170 (-7.33%)
At close: Mar 17, 2026, 4:00 PM EDT
2.124
-0.026 (-1.20%)
After-hours: Mar 17, 2026, 5:17 PM EDT
Equillium Employees
Equillium had 35 employees as of December 31, 2024. The number of employees decreased by 9 or -20.45% compared to the previous year.
Employees
35
Change
-9
Growth
-20.45%
Revenue / Employee
$125,486
Profits / Employee
-$697,629
Market Cap
130.92M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 35 | -9 | -20.45% |
| Sep 30, 2024 | 45 | 0 | - |
| Jun 30, 2024 | 45 | -2 | -4.26% |
| Mar 31, 2024 | 44 | 7 | 18.92% |
| Dec 31, 2023 | 44 | 8 | 22.22% |
| Sep 30, 2023 | 45 | 0 | - |
| Jun 30, 2023 | 47 | 2 | 4.44% |
| Mar 31, 2023 | 37 | -10 | -21.28% |
| Dec 31, 2022 | 36 | -9 | -20.00% |
| Sep 30, 2022 | 45 | 0 | - |
| Jun 30, 2022 | 45 | - | - |
| Mar 31, 2022 | 47 | 16 | 51.61% |
| Dec 31, 2021 | 45 | 14 | 45.16% |
| Dec 31, 2020 | 31 | 15 | 93.75% |
| Sep 30, 2020 | 26 | 10 | 62.50% |
| Jun 30, 2020 | 22 | 6 | 37.50% |
| Mar 31, 2020 | 22 | 7 | 46.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 188 |
| Sangamo Therapeutics | 183 |
| Innate Pharma | 174 |
| Fate Therapeutics | 161 |
| Rani Therapeutics Holdings | 106 |
| Cardiff Oncology | 31 |
| Ovid Therapeutics | 23 |
| AN2 Therapeutics | 22 |
EQ News
- 4 days ago - Equillium Announces $35 Million Financing with RA Capital Management - GlobeNewsWire
- 19 days ago - Equillium: Multi-Cytokine Platform To Go Beyond Scope Of EQ504 For UC - Seeking Alpha
- 20 days ago - Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Equillium to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update - GlobeNewsWire
- 4 months ago - Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript - Seeking Alpha
- 5 months ago - Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 - GlobeNewsWire